NASDAQ:BIIB - Nasdaq - US09062X1037 - Common Stock - Currency: USD
116.49
-2.12 (-1.79%)
The current stock price of BIIB is 116.49 USD. In the past month the price decreased by -17.32%. In the past year, price decreased by -44.24%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.81 | 301.01B | ||
AMGN | AMGEN INC | 13.81 | 147.14B | ||
GILD | GILEAD SCIENCES INC | 22.63 | 130.06B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1646.62 | 122.76B | ||
REGN | REGENERON PHARMACEUTICALS | 12.3 | 61.38B | ||
ARGX | ARGENX SE - ADR | 320.27 | 36.37B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.28B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.70B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.47B | ||
NTRA | NATERA INC | N/A | 19.23B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.60B | ||
UTHR | UNITED THERAPEUTICS CORP | 11.55 | 12.77B |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,605 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7570
Company Website: https://www.biogen.com/
Investor Relations: https://investors.biogen.com
Phone: 17814642000
The current stock price of BIIB is 116.49 USD. The price decreased by -1.79% in the last trading session.
The exchange symbol of BIOGEN INC is BIIB and it is listed on the Nasdaq exchange.
BIIB stock is listed on the Nasdaq exchange.
43 analysts have analysed BIIB and the average price target is 200.75 USD. This implies a price increase of 72.33% is expected in the next year compared to the current price of 116.49. Check the BIOGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOGEN INC (BIIB) has a market capitalization of 17.05B USD. This makes BIIB a Large Cap stock.
BIOGEN INC (BIIB) currently has 7570 employees.
BIOGEN INC (BIIB) has a support level at 115.17 and a resistance level at 116.89. Check the full technical report for a detailed analysis of BIIB support and resistance levels.
The Revenue of BIOGEN INC (BIIB) is expected to decline by -4.32% in the next year. Check the estimates tab for more information on the BIIB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BIIB does not pay a dividend.
BIOGEN INC (BIIB) will report earnings on 2025-05-01, before the market open.
The PE ratio for BIOGEN INC (BIIB) is 7.07. This is based on the reported non-GAAP earnings per share of 16.47 and the current share price of 116.49 USD. Check the full fundamental report for a full analysis of the valuation metrics for BIIB.
The outstanding short interest for BIOGEN INC (BIIB) is 2.56% of its float. Check the ownership tab for more information on the BIIB short interest.
ChartMill assigns a fundamental rating of 5 / 10 to BIIB. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 16.47. The EPS increased by 9.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.87% | ||
ROA | 5.82% | ||
ROE | 9.76% | ||
Debt/Equity | 0.27 |
ChartMill assigns a Buy % Consensus number of 74% to BIIB. The Buy consensus is the average rating of analysts ratings from 43 analysts.
For the next year, analysts expect an EPS growth of -2.34% and a revenue growth -4.32% for BIIB